<SEC-DOCUMENT>0001193125-16-583865.txt : 20160509
<SEC-HEADER>0001193125-16-583865.hdr.sgml : 20160509
<ACCEPTANCE-DATETIME>20160509162106
ACCESSION NUMBER:		0001193125-16-583865
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160509
DATE AS OF CHANGE:		20160509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		161631941

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d193757d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;9, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARDELYX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36485</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-1303944</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>34175 Ardenwood Blvd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, CA 94555 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (510)&nbsp;745-1700 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2016, Ardelyx, Inc. (the
&#147;Company&#148;) announced its financial results for the first quarter ended March&nbsp;31, 2016. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 2.02 shall not be considered &#147;filed&#148; under the Securities Exchange Act of 1934, as amended, nor shall it
be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&nbsp;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is
to be considered &#147;filed&#148; or incorporated by reference therein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits.</B> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;9, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">ARDELYX, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Kaufmann</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Kaufmann</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d193757dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g193757g44a51.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14.00em; font-size:10pt; font-family:Times New Roman">34175&nbsp;Ardenwood&nbsp;Blvd</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14.00em; font-size:10pt; font-family:Times New Roman">Fremont, CA 94555</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14.00em; font-size:10pt; font-family:Times New Roman">(510)
745-1700 &#150; Tele</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14.00em; font-size:10pt; font-family:Times New Roman">(510) 745-0493 &#150; Fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:14.00em; font-size:10pt; font-family:Times New Roman">www.ardelyx.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx Reports First Quarter 2016 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference Call and Webcast Today at 4:30 p.m. ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FREMONT, Calif., May&nbsp;9, 2016 /PRNewswire/ &#151;&nbsp;Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on
gastrointestinal and cardio-renal diseases, today announced financial results for the first quarter ended March&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased
with the progress we have made thus far in 2016,&#148; said Mike Raab, President and Chief Executive Officer of Ardelyx. &#147;The remainder of the year looks to be an exciting period for Ardelyx, as we expect to execute on multiple upcoming
milestones. We expect results from the second Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia in ESRD patients in the second half of 2016. We look forward to building upon the positive results from our clinical
trial evaluating the pharmacodynamic activity of the lead product candidate from our RDX022 program in healthy volunteers, which we announced in January, and we plan to initiate a Phase 3 clinical trial in patients with hyperkalemia during the
fourth quarter 2016. In the fourth quarter, we also expect to submit an IND for RDX98940, the lead development candidate from our RDX009 program.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Highlights from the First Quarter 2016 and Upcoming Clinical Milestones </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completed an underwritten follow-on public offering of common stock in January 2016, with net proceeds totaling approximately $80.8 million; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reported positive results from the pharmacodynamic (PD) clinical trial evaluating the activity of RDX227675, the lead product candidate from our RDX022 program, in 60 healthy adult volunteers in January 2016. RDX227675
successfully demonstrated the ability to bind potassium in the gastrointestinal tract and was generally well-tolerated at all doses administered up to 27.5 g/day; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ardelyx plans to proceed with a Phase 3 clinical trial for RDX227675, which it currently intends to initiate in the fourth quarter 2016. Ardelyx expects to pursue FDA approval for RDX227675 using the 505(b)(2)
regulatory pathway; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Results from the second Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients are expected in the second half of 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ardelyx currently expects to file an IND in the fourth quarter of 2016 for RDX98940, Ardelyx&#146;s lead development candidate in its RDX009 program; RDX98940 is a minimally-systemic TGR5 agonist that stimulates local
secretion of GLP-1 and GLP-2 in the gastrointestinal tract; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Results from T3MPO-1 and T3MPO-2, two ongoing Phase 3 clinical trials evaluating tenapanor for the treatment of <FONT STYLE="white-space:nowrap">IBS-C,</FONT> are expected in 2017. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>First Quarter Ended March&nbsp;31, 2016 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss for the first quarter of 2016 was $23.5 million, or $0.70 per basic and diluted share, compared to a net loss of $3.5 million, or $0.19 per basic and
diluted share for the first quarter of 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total revenue is comprised of licensing revenue and collaborative development revenue. Licensing revenue for the
first quarter of 2016 decreased to zero from $3.9 million for the first quarter of 2015. Licensing revenue for the three months ended March&nbsp;31, 2015 related to the recognition of revenue from upfront and milestone payments received from
AstraZeneca. As our collaboration agreement with AstraZeneca was terminated in June 2015, there was no further recognition of revenue related to the upfront and milestone payments after the six-month period ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborative development revenue is comprised of development expenses that were reimbursable to Ardelyx by AstraZeneca. Collaborative development revenue for
the first quarter of 2016 decreased to zero from $2.0 million for the first quarter of 2015. The decrease was attributable to the termination of the AstraZeneca agreement in June 2015 and related cessation of reimbursement of research and
development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense for the first quarter of 2016 increased to $19.3 million from $6.2 million for the first quarter
of 2015. The increase was due to expenses incurred primarily for clinical development activities as well as clinical manufacturing and process development activities associated with tenapanor and RDX227675. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $4.3 million for the first quarter of 2016 as compared to $3.2 million for first quarter of 2015. The increase was
primarily due to an increase in professional services fees, personnel and public company costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents were $171.7 million as of
March&nbsp;31, 2016 compared with $107.0 million as of December&nbsp;31, 2015 primarily because of an underwritten public offering completed in January 2016 that yielded approximately $80.8 million in net proceeds, offset by $16.1 million in cash
required for operating and other activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call&nbsp;&amp; Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx management will host a live conference call and webcast today at 4:30 p.m. ET&nbsp;to discuss the financial results for the first quarter ended
March&nbsp;31, 2016. The live webcast and a replay may be accessed by visiting the investor relations section of the Ardelyx website at ir.ardelyx.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please connect to the Company&#146;s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be
needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the live conference call. The conference ID number for the live call is 1292888. Please dial in approximately 10 minutes prior
to the call. An archived webcast replay will be available on the Company&#146;s website until May&nbsp;23, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ardelyx, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small
molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner,
to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of constipation-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 5 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end-stage renal disease. In addition to tenapanor, Ardelyx is developing RDX227675, a
non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in
Fremont, California. For more information, please visit Ardelyx&#146;s website at www.ardelyx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements
reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for tenapanor in treating IBS-C and hyperphosphatemia in end-stage renal disease
patients, Ardelyx&#146;s future development plans for tenapanor and the timing thereof,&nbsp;the expected timing for the receipt of results from T3MPO-1 and T3MPO-2, the two ongoing Phase 3 clinical trials evaluating tenapanor for the treatment of
IBS-C, the expected timing for the receipt of the results for the Phase 2b hyperphosphatemia clinical trial, the potential for RDX227675 in treating hyperkalemia in kidney and heart disease patients, Ardelyx&#146;s future development plans for
RDX227675 and the timing thereof, the expected timing for the initiation of the Phase 3 clinical trial for RDX227675, the expected timing for the filing of an IND for RDX98940, and the potential of Ardelyx&#146;s drug discovery and design platform.
Such forward-looking statements involve substantial risks and uncertainties that could cause the development of tenapanor, RDX227675, or Ardelyx&#146;s&nbsp;future results, performance or achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development process and the uncertainties in the manufacture of clinical trial material, including
process development, scale up and tech transfer of manufacturing processes.&nbsp;Ardelyx&nbsp;undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx&#146;s business in general, please refer to Ardelyx&#146;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on May&nbsp;9, 2016, and its future current and periodic reports to be filed with the Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 5 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;March&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Derived from the audited financial statements included on Form 10-K for the year ended December&nbsp;31, 2015. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed
Statements of Operations and Comprehensive Loss </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaborative development revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares used in computing basic and diluted net loss per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,466,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,606,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 5 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor and Media Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Kaufmann </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mkaufmann@ardelyx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">510-745-1751 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Investors: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bill Slattery, Jr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burns McClellan on behalf of Ardelyx Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">bslattery@burnsmc.com
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212-213-0006 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOURCE Ardelyx, Inc.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 5 Pages </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g193757g44a51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g193757g44a51.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !- 18# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "F
M.2O]*<3@5\,_\%WOVZ-9_8Y_9AL].\(WQT[QCX_NGTVSNXS^]L;9%#3S)Z/@
MJBGL7SU KKP&#J8O$0PU+XI.QCB*\:-)U9[(^J_%_P"TEX"\!ZZ-,UOQUX2T
M;4<X:TO=6MX9A]59P1^-=CIFJPZQ8Q75K<0W5M.N^*6%PZ2*>A##@CZ5_(]J
ME_)KFHS75]-+=WMTYDDN+B3S))6/)9F8DLQZY)).:^_O^""7[?GB#X*_M1:+
M\+=7U:ZO/ 7CJ1K&WL[B4NFE7Q!:*2(D_*'(*,HP/F!QD5]_F_AW4PN$>(I5
M>:4%=JWWV/F\'Q+&K65.HK)[?\$_>O<=M<]\0?BOX<^$ND17_BGQ!HWAVRFE
M$*7&HW<=M$[D9"!G(!/!XKHHQLC^@K\V?^#G5D;]B'PGYFW'_"7V^-W_ %[S
MU\+E."6-QE/"R=N9VN?08W$.A0E52O8^U?\ AMKX0?\ 14O '_@]MO\ XNC_
M (;:^$'_ $5+P!_X/;;_ .+K^5P?9_\ IC^E'^C_ /3']*_4_P#B&&'?_+]_
M<CY3_6JK_P ^T?U3VG[9OPEU"Y2&#XG^ 7ED.%4:[;98_P#?=>BZ1JUOK>GI
M<VES;W=O*,QS02"2.0>H8<&OY% L#G_EE^&*^C/V!O\ @I1\0?V"/B+8WFD:
MI?:EX.>=1JOANXN&>TNH<_,8PQ_=2@9*LO?KD5Y^8^&DZ=)U,)5YFNC7^1T8
M?BA2FE6A9/K?]#^D/X@_%OPW\)M-BO?%'B'1O#ME/+Y$4^I7<=M'))@G:K.0
M"< G%<E_PVS\(0/^2I> /_![;?\ Q=? /_!Q+\2=&^-7_!.WX5^+-!N%O=$\
M1Z_;7]E+C[T<EK*P!'9AT([$$5^+C0PQC)6-1TR0*X.&^!J>981XBM5<&FU:
MW5&V99_+#5O9PA=63W[G]4/_  VU\(/^BI> /_![;?\ Q=;O@W]HKP%\1+E8
M- \<^$M:G;I%9:M;SN?^ JQ/Z5_)_P#N/^F/Z5)9W/V*X66VE,$Z'<CPN4=3
MV(*\BO=?A?1:M3Q#OYI?H<7^M53[5/0_KN5R#S3@??\ 2OP%_P"":?\ P7#\
M>?LN^,M-\.?$75M2\9?#:YD6"1[R0SZAH:GCS8I#\TB+WC8GC."",']PO'/Q
MU\-> ?@=J'Q$O=3AD\)Z;I3:TU]$0Z36P3S%9#WW# 7_ 'A7YWG?#F,RVO&C
M65^;2+77_@^1]%@<THXJFYPTMO<ZW5-9M]$T^2[O+J"SMH>7EN)%CC4>I8X
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MD) ."./>NA4\5^#?_!OS^VH/V>_VG6^'FL78A\+?$PK!!O.V.UU) ?)<>GF
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MT_:K'"W4_P"_F_$ Q _05^\7C+Q1:>"?#&HZS?RK#8Z3:RWMPY_ACC0NQ_
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M#G"RQJ^/J"2/P-3?$OX->%/C-HT6G>+?#FB>)M.@E$\=KJEG'=1)( 0'"N"
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M?!XFE+"8RI1I;2C^9J_\$L/V0=/_ &W?VTO#?@K6Y94\.K%/JFKB)]LEQ;P
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M0=3DY5?:_6QY>:YC]2IJI:Y^U_\ P6^^/I^%G_!.#Q8^BR-=7_C3RO#]E):
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M[2_.UI;9-:W^\Y7C?[0A6P_+9Q1\/_\ !M3^T!_PK[]K_7O ES.5L?'VD-)
MI.%-W:9D4_4QM*/PK]?OVV_VF]/_ &/_ -E_Q=\0M0B6Z'A^T+VMLQP+JY<B
M.&,^S2,H/H,FOYJ/V2/C;/\ LY_M,> O'<+&/_A&M:M[J8#O!O"S+^,98?\
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M/VI_#7B'X>Z!H?C:VU?Q5H.IV=I+>6<201O]BF;YR)"0,*:_&C]G8?\ %\/
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93%1HFT=3BINM)M%.W5 -B]:*?C%%,#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
